Security key
98943L107
Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL)
CUSIP: 98943L107
Q1 2025 13F Holders as of 31 Mar 2025
- Type / Class
- Equity / Common Stock,$0.001 par value per share
- Shares outstanding
- 72,096,078
- Total 13F shares
- 58,450,755
- Share change
- -5,727,939
- Total reported value
- $92,928,558
- Put/Call ratio
- 538%
- Price per share
- $1.59
- Number of holders
- 131
- Value change
- -$20,527,901
- Number of buys
- 59
- Number of sells
- 75
Report period
Q1 2025
Institutions
131
Top holders
10
ZNTL full security history
Newer quarter: Q2 2025
Previous quarter: Q4 2024
Zentalis Pharmaceuticals, Inc. SEC filings
Zentalis Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98943L107
Recent filing periods:
Top shareholders of ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Walters William T. |
13D/G
|
— |
9.9%
|
7,050,000
|
$10,081,500 | +$786,500 | 29 Jan 2025 | |
| VANGUARD GROUP INC |
13F
13D/G
|
Company · The Vanguard Group |
4.6%
from 13D/G
|
3,271,240
|
$9,911,858 | — | 31 Dec 2024 | |
| FMR LLC |
13F
13D/G
|
Company |
0.2%
from 13D/G
|
182,309
|
$552,396 | — | 31 Dec 2024 | |
| Matrix Capital Management Company, LP |
13F
|
Company |
19%
|
13,959,973
|
$42,298,718 | — | 31 Dec 2024 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
6.2%
|
4,475,054
|
$13,558,372 | — | 31 Dec 2024 | |
| BlackRock, Inc. |
13F
|
Company |
5.9%
|
4,238,089
|
$12,841,409 | — | 31 Dec 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
4.5%
|
3,216,727
|
$9,746,683 | — | 31 Dec 2024 | |
| Decheng Capital LLC |
13F
|
Company |
3.2%
|
2,338,095
|
$7,084,428 | — | 31 Dec 2024 | |
| Opaleye Management Inc. |
13F
|
Company |
2.5%
|
1,767,500
|
$5,355,525 | — | 31 Dec 2024 | |
| MORGAN STANLEY |
13F
|
Company |
2.4%
|
1,713,188
|
$5,190,960 | — | 31 Dec 2024 | |
| Almitas Capital LLC |
13F
|
Company |
2.3%
|
1,626,896
|
$4,929,495 | — | 31 Dec 2024 | |
| PRIMECAP MANAGEMENT CO/CA/ |
13F
|
Company |
2.1%
|
1,520,630
|
$4,607,509 | — | 31 Dec 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.8%
|
1,312,964
|
$3,979,412 | — | 31 Dec 2024 | |
| STATE STREET CORP |
13F
|
Company |
1.8%
|
1,288,985
|
$3,905,625 | — | 31 Dec 2024 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
1.7%
|
1,239,459
|
$3,755,561 | — | 31 Dec 2024 | |
| Verition Fund Management LLC |
13F
|
Company |
1.7%
|
1,217,094
|
$3,687,795 | — | 31 Dec 2024 | |
| MPM BioImpact LLC |
13F
|
Company |
1.5%
|
1,106,851
|
$3,353,759 | — | 31 Dec 2024 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
1.5%
|
1,067,233
|
$3,229,000 | — | 31 Dec 2024 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
1.5%
|
1,050,000
|
$3,181,500 | — | 31 Dec 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
1.4%
|
979,855
|
$2,970,000 | — | 31 Dec 2024 | |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD |
13F
|
Company |
1.3%
|
961,486
|
$2,913,303 | — | 31 Dec 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.3%
|
957,563
|
$2,901,416 | — | 31 Dec 2024 | |
| PFIZER INC |
13F
|
Company |
1.3%
|
953,834
|
$2,890,117 | — | 31 Dec 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.3%
|
918,107
|
$2,781,865 | — | 31 Dec 2024 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
1.2%
|
889,700
|
$2,695,791 | — | 31 Dec 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
1.2%
|
859,710
|
$2,604,922 | — | 31 Dec 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.89%
|
641,407
|
$1,943,464 | — | 31 Dec 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.86%
|
616,800
|
$1,868,904 | — | 31 Dec 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.75%
|
539,345
|
$1,634,215 | — | 31 Dec 2024 | |
| Woodline Partners LP |
13F
|
Company |
0.74%
|
530,582
|
$1,607,663 | — | 31 Dec 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.7%
|
505,006
|
$1,530,075 | — | 31 Dec 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.69%
|
497,362
|
$1,507,007 | — | 31 Dec 2024 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.69%
|
493,982
|
$1,496,766 | — | 31 Dec 2024 | |
| 5AM Venture Management, LLC |
13F
|
Company |
0.68%
|
490,000
|
$1,484,700 | — | 31 Dec 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.67%
|
484,738
|
$1,468,756 | — | 31 Dec 2024 | |
| Boxer Capital Management, LLC |
13F
|
Company |
0.62%
|
450,000
|
$1,363,500 | — | 31 Dec 2024 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
0.48%
|
345,039
|
$1,045,468 | — | 31 Dec 2024 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.45%
|
323,514
|
$980,247 | — | 31 Dec 2024 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.32%
|
232,058
|
$703,136 | — | 31 Dec 2024 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.31%
|
223,097
|
$675,984 | — | 31 Dec 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.3%
|
215,999
|
$654,477 | — | 31 Dec 2024 | |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC |
13F
|
Company |
0.28%
|
200,113
|
$606,342 | — | 31 Dec 2024 | |
| Walleye Capital LLC |
13F
|
Company |
0.27%
|
193,709
|
$586,938 | — | 31 Dec 2024 | |
| UBS Group AG |
13F
|
Company |
0.25%
|
183,678
|
$556,544 | — | 31 Dec 2024 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.25%
|
180,224
|
$546,077 | — | 31 Dec 2024 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.24%
|
176,292
|
$534,165 | — | 31 Dec 2024 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.24%
|
175,000
|
$530,250 | — | 31 Dec 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.23%
|
162,935
|
$493,693 | — | 31 Dec 2024 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.2%
|
146,673
|
$444,419 | — | 31 Dec 2024 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.2%
|
144,170
|
$437,000 | — | 31 Dec 2024 |
Institutional Holders of Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL) as of Q1 2025
As of 31 Mar 2025,
Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL) was held by
131 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
58,450,755 shares.
The largest 10 holders included
Matrix Capital Management Company, LP, BlackRock, Inc., VANGUARD GROUP INC, MILLENNIUM MANAGEMENT LLC, ACADIAN ASSET MANAGEMENT LLC, Decheng Capital LLC, Opaleye Management Inc., Almitas Capital LLC, TANG CAPITAL MANAGEMENT LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
131
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2025 vs Q4 2024 Across Filers
Q4 2024 holders
141
Q1 2025 holders
131
Holder diff
-10
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 Value $ | Q1 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.